LY3031207

CAS No. 1381846-21-4

LY3031207 ( LY 3031207 )

Catalog No. M11582 CAS No. 1381846-21-4

A novel potent (IC50=910 ng/mL), highly selective microsomal prostaglandin E synthase 1 inhibitor (mPGES-1) for treatment of undisclosed indications.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 Get Quote
50MG 1782 Get Quote
100MG 2250 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    LY3031207
  • Note
    Research use only, not for human use.
  • Brief Description
    A novel potent (IC50=910 ng/mL), highly selective microsomal prostaglandin E synthase 1 inhibitor (mPGES-1) for treatment of undisclosed indications.
  • Description
    A novel potent (IC50=910 ng/mL), highly selective microsomal prostaglandin E synthase 1 inhibitor (mPGES-1) for treatment of undisclosed indications.
  • Synonyms
    LY 3031207
  • Pathway
    Immunology/Inflammation
  • Target
    PGE synthase
  • Recptor
    PGE synthase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1381846-21-4
  • Formula Weight
    334.80
  • Molecular Formula
    C16H19ClN4O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(NC1=NC=CN1)C2=CC(CNC(C(C)(C)C)=O)=CC=C2Cl
  • Chemical Name
    2-chloro-N-(1H-imidazol-2-yl)-5-(pivalamidomethyl)benzamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • LY3031207

    A novel potent (IC50=910 ng/mL), highly selective microsomal prostaglandin E synthase 1 inhibitor (mPGES-1) for treatment of undisclosed indications.

  • GSK-2894631A

    HPGDS inhibitor 2 is a potent, selective hematopoietic prostaglandin D synthase (h-pgds) inhibitor.

  • Crisdesalazine

    Crisdesalazine (AAD-2004, AAD2004) is a derivative of aspirin that inhibits microsomal PGE(2) synthase-1 (mPGES-1) activity in response to both LPS-treated BV2 cell with IC50 of 230 nM and recombinant human mPGES-1 protein with IC50 of 249 nM in vitro.